Leukemia · 2022 · 95 citations · 28 references
Life SciencesGeneticsMolecular GeneticsCytogeneticsGenomicsMedical GeneticsChromosome AberrationsGenomic ProfilingMolecular CytogeneticsMyelodysplastic SyndromesStructural Variant AnalysisVariant DetectionChromosomal Aberration MappingChromosome RearrangementsClinical Cytogenetic DiagnosticsCytogenetic AberrationsCytogenetic AbnormalitiesGenomic RearrangementsTp53 MutationsVariant Interpretation In Cytogenetics
Chromosome banding analysis (CBA) remains the standard-of-care for structural variant (SV) assessment in MDS. Optical genome mapping (OGM) is a novel, non-sequencing-based technique for high-resolution genome-wide SV profiling (SVP). We explored the clinical value of SVP by OGM in 101 consecutive, newly diagnosed MDS patients from a single-center, who underwent standard-of-care cytogenetic and targeted NGS studies. OGM detected 383 clinically significant, recurrent and novel SVs. Of these, 224 (51%) SVs, seen across 34% of patients, were cryptic by CBA (included rearrangements involving MECOM, NUP98::PRRX2, KMT2A partial tandem duplications among others). SVP decreased the proportion of normal karyotype by 16%, identified complex genomes (17%), chromothripsis (6%) and generated informative results in both patients with insufficient metaphases. Precise gene/exon-level mapping allowed assessment of clinically relevant biomarkers (TP53 allele status, KMT2A-PTD) without additional testing. SV data was complementary to NGS. When applied in retrospect, OGM results changed the comprehensive cytogenetic scoring system (CCSS) and R-IPSS risk-groups in 21% and 17% patients respectively with an improved prediction of prognosis. By multivariate analysis, CCSS by OGM only (not CBA), TP53 mutation and BM blasts independently predicted survival. This is the first and largest study reporting the value of combined SVP and NGS for MDS prognostication.
28
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg, Heinz Tuechler, Julie Schanz et al. · Blood · 2012 · 3.1K citations · Full text
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil, Moritz Gerstung, Luca Malcovati et al. · Blood · 2013 · 1.8K citations
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar, Kristen E. Stevenson, Omar Abdel‐Wahab et al. · New England Journal of Medicine · 2011 · 1.6K citations
Medicine, Genetics, Hematology +17
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
Elsa Bernard, Heinz Tuechler, Peter L. Greenberg et al. · NEJM Evidence · 2022 · 813 citations · Full text
Medicine, Genetics, Hematology +16
Julie Schanz, Heinz Tüchler, Françesc Solé et al. · Journal of Clinical Oncology · 2012 · 691 citations · Full text
Medicine, Hematology, Oncology +17